Marriage Counselors in Port Huron, MI Accepting Medicare
3 Marriage Counselors found. Showing 1 - 3
 Chelsea Renee Kendrick-singh Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 2601 13th St, Port Huron, MI 48060 Phone: 810-987-9100 |
Mrs. Gena Marie Voit, MA, MFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1220 6th St, Port Huron, MI 48060 Phone: 810-987-8772 |
Kathleen Von Kampen Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 520 Superior St, Port Huron, MI 48060 Phone: 810-455-0102 |
News Archive
Canadians are unhappy with the current Medicare system
A vast majority of Canadians polled assigned the health care system an overall B grade. Almost all Canadians feel sustainability of the health care system hinges on guaranteeing timely access to health care services. Two-thirds agree with making increased federal funds conditional on improved monitoring and accountability
Viewpoints: Bowles urges 'deficit deal now;' A doctor's take on health law; Preparing N.Y. hospitals for future storms
Going over the fiscal cliff would mean allowing a massive and immediate cut to nearly every major government agency and activity, including those vital to our national security or economic growth.
Reprogrammed endothelial cells for treatment of vascular disorders
A research team at Weill Cornell Medical College has discovered a way to utilize diagnostic prenatal amniocentesis cells, reprogramming them into abundant and stable endothelial cells capable of regenerating damaged blood vessels and repairing injured organs.
Myriad Genetics expands companion diagnostic collaboration with AstraZeneca
Myriad Genetics, Inc. today announced the expansion of its companion diagnostic collaboration with AstraZeneca. Under the terms of the expanded agreement, Myriad's BRACAnalysis CDx test will be used to prospectively identify which patients with metastatic pancreatic cancer may respond to treatment with Lynparza (olaparib).
AstraZeneca's CRESTOR approved for treating pediatric patients with HeFH
AstraZeneca today announced the U.S. Food and Drug Administration (FDA) approved CRESTOR® (rosuvastatin calcium) for use in pediatric patients ages 10-17 with heterozygous familial hypercholesterolemia (HeFH) when diet therapy fails to reduce elevated cholesterol. HeFH, a genetic disease, is characterized by high LDL cholesterol (the "bad" cholesterol) and increased risk of early cardiovascular disease.
› Verified 6 days ago
Counselors
Clinical Social Workers
Pharmacists
Dentists
Occupational Therapists
Psychologists